Elutia Inc. ELUT

ELUT Company Overview

Elutia Inc. is a commercial-stage biotechnology and medical technology company focused on developing and commercializing drug-eluting biomatrix products used in surgery and implantable medical applications. The company operates primarily in the regenerative medicine and implantable-device sectors, with products designed to improve healing, reduce complications, and enhance tissue compatibility in surgical procedures. Elutia’s portfolio includes biologic and bioengineered products used in breast reconstruction, cardiovascular applications, wound care, and orthopedic procedures.

The company’s primary revenue drivers include sales of its biologic matrices and antibiotic-eluting biomaterial technologies, particularly products intended to reduce infection risk associated with implanted medical devices. Elutia serves hospitals, surgeons, and healthcare systems primarily in the United States, while also maintaining select international commercial relationships. The company evolved from Aziyo Biologics, Inc., which itself was formed through the merger of regenerative medicine and tissue technology businesses. In 2023, the company rebranded to Elutia Inc. to emphasize its strategic focus on biologic matrices and drug-eluting biomaterial platforms.